Literature DB >> 27714465

IgA nephropathy with presentation of nephrotic syndrome at onset in children.

Yuko Shima1, Koichi Nakanishi2, Masashi Sato1, Taketsugu Hama1, Hironobu Mukaiyama1, Hiroko Togawa1, Ryojiro Tanaka3, Kandai Nozu4, Mayumi Sako5, Kazumoto Iijima4, Hiroyuki Suzuki1, Norishige Yoshikawa6.   

Abstract

BACKGROUND: Despite a low incidence, nephrotic syndrome (NS) can present with IgA nephropathy (IgAN). The clinical characteristics and long-term outcomes of pediatric patients with IgAN presenting with NS (NS-IgAN) at onset have not been fully elucidated.
METHODS: We retrospectively analyzed 426 patients, and compared clinical and pathological (Oxford) findings between those with NS-IgAN and those with non-NS-IgAN.
RESULTS: Among 426 patients, 30 (7.0 %) had NS-IgAN. Logistic analyses showed that male sex (OR: 7.6, p = 0.0002), M1 (OR: 10.3, p = 0.002), and E1 (OR: 15.2, p = 0.0001) were significantly related to NS. The mean observation period was 6.2 ± 3.2 years. Although NS-IgAN was associated with significantly lower renal survival than non-NS-IgAN according to Kaplan-Meier analysis (p = 0.02), renal survival of NS-IgAN was good (92.4 % at 10 years). The most significant prognostic factor for renal survival was remission of proteinuria after treatment, and NS at onset is also a significant prognostic factor for renal survival after adjusting for remission of proteinuria. Twenty children with NS-IgAN were treated with prednisolone alone, or prednisolone and immunosuppressant. Remission of proteinuria occurred in 21 patients. Three cases of NS-IgAN progressed to stage III-V chronic kidney disease at the most recent observation. They all demonstrated heavy proteinuria after the 2-year initial treatment. The significant factor for persistent proteinuria at 5 years was S1 in NS-IgAN.
CONCLUSIONS: The most significant factor for renal survival was responsiveness to treatment, not NS itself. As modifiable acute lesions are the dominant pathological findings in NS-IgAN, histological improvements achieved by appropriate treatments can result in a favorable prognosis.

Entities:  

Keywords:  End-stage renal disease; IgA nephropathy; Nephrotic syndrome; Remission of proteinuria

Mesh:

Substances:

Year:  2016        PMID: 27714465     DOI: 10.1007/s00467-016-3502-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  30 in total

1.  Urinary screening of elementary and junior high-school children over a 13-year period in Tokyo.

Authors:  M Murakami; H Yamamoto; Y Ueda; K Murakami; K Yamauchi
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

Review 2.  Pathophysiology and treatment of IgA nephropathy in children.

Authors:  N Yoshikawa; R Tanaka; K Iijima
Journal:  Pediatr Nephrol       Date:  2001-05       Impact factor: 3.714

3.  Mesangial IgA deposits with steroid responsive nephrotic syndrome: probable minimal lesion nephrosis.

Authors:  P Sinnassamy; S O'Regan
Journal:  Am J Kidney Dis       Date:  1985-05       Impact factor: 8.860

4.  Proteinuria screening for children.

Authors:  Mutsumi Murakami; Mari Hayakawa; Tsuyoshi Yanagihara; Yoshitaka Hukunaga
Journal:  Kidney Int Suppl       Date:  2005-04       Impact factor: 10.545

5.  Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  J Pediatr       Date:  1982-10       Impact factor: 4.406

6.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

Authors:  Ian S D Roberts; H Terence Cook; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Daniel C Cattran; Rosanna Coppo; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

7.  Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial.

Authors:  Manuel Praga; Eduardo Gutiérrez; Ester González; Enrique Morales; Eduardo Hernández
Journal:  J Am Soc Nephrol       Date:  2003-06       Impact factor: 10.121

8.  Prognostic indicators in childhood IgA nephropathy.

Authors:  N Yoshikawa; H Ito; H Nakamura
Journal:  Nephron       Date:  1992       Impact factor: 2.847

9.  IgA nephropathy with minimal change disease.

Authors:  Leal C Herlitz; Andrew S Bomback; Michael B Stokes; Jai Radhakrishnan; Vivette D D'Agati; Glen S Markowitz
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

10.  IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.

Authors:  Rosanna Coppo; Licia Peruzzi; Alessandro Amore; Antonio Piccoli; Pierre Cochat; Rosario Stone; Martin Kirschstein; Tommy Linné
Journal:  J Am Soc Nephrol       Date:  2007-05-18       Impact factor: 10.121

View more
  3 in total

Review 1.  Steroid therapy in children with IgA nephropathy.

Authors:  Alexandra Cambier; Olivia Boyer; Georges Deschenes; James Gleeson; Anne Couderc; Julien Hogan; Thomas Robert
Journal:  Pediatr Nephrol       Date:  2019-02-18       Impact factor: 3.714

2.  Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome.

Authors:  Xin Han; Yi Xiao; Yi Tang; Xiaonan Zheng; Mawluda Anwar; Wei Qin
Journal:  Clin Exp Med       Date:  2019-09-21       Impact factor: 3.984

3.  Primary IgA nephropathy with nephrotic-range proteinuria in Chinese children.

Authors:  Jing-Li Zhao; Jing-Jing Wang; Guo-Ping Huang; Chun-Yue Feng
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.